eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2021
vol. 25
 
Share:
Share:
abstract:
Original paper

The antitumour effect of galangin and luteolin with doxorubicin on chemically induced hepatocellular carcinoma in rats

Gamal Atwa
1
,
Gamal Omran
2
,
Atef Abd Elbaky
1
,
Tarek Okda
2

  1. Department of Biochemistry, Faculty of Pharmacy, Port-Said University, Port-Said, Egypt
  2. Department of Biochemistry, Faculty of Pharmacy, Damanhur University, Damanhur, Egypt
Contemp oncol (Pozn) 2021; 25 (3): 174–184
Online publish date: 2021/10/14
View full text Get citation
 
PlumX metrics:
Egypt

Hepatocellular carcinoma (HCC), a highly malignant tumour with very high morbidity and mortality, remains the second cause of cancer-related deaths worldwide. Galangin is a naturally occurring flavonoid extracted from the propolis and root of Alpinia officinarum, which possesses antitumour efficacy, which has resulted in an increase in interest in related research. Additionally, galangin inhibits cell proliferation and induces apoptosis in several human malignancies. On the other hand, luteolin, a naturally occurring flavonoid found in a variety of edible plants, augments cytotoxicity in different cancer cells through the inhibition of cell-survival pathways and activation of apoptosis. Moreover, luteolin blocks the activity of anti-apoptotic Bcl-2 family members. The present study aimed to assess the antitumour effect of galangin and luteolin in combination and the antitumour effect of a combination of galangin and luteolin together with doxorubicin (DOX) in a chemically induced HCC rat model. Our analyses demonstrated that the combination treatment with galangin, luteolin, and DOX showed the greatest antineoplastic activity against HCC, which was observed by significant decreases in the levels of HCC markers, including serum -fetoprotein-L3, and hepatic tissue expression of both glypican 3 and heat shock proteins. On the other hand, the hepatic tissue expression of caspase-3 was significantly increased. These results suggest that combination treatment with galangin and luteolin is a promising candidate for clinical use in HCC chemotherapy, especially when used in combination with DOX.
keywords:

α-fetoprotein-L3, caspase-3, diethyl nitrosamine, galangin, hepatocellular carcinoma

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.